Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Radiation's hidden immune impact: key to better cervical cancer treatment?

NCT ID NCT06804135

Knowledge-focused Sponsor: Tata Memorial Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how pelvic radiation therapy changes the immune system in people with cervical cancer. Researchers want to understand if radiation helps or hurts the body's ability to fight cancer long-term. About 110 participants will provide blood and tumor samples before, during, and after treatment. The goal is to use this information to improve radiation plans and lower the chance of cancer coming back.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 110 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Jan 2030

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will include patients that are undergoing radiation treatment for primary radiation or reirradiation for cervical cancer.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Common Inclusion Criteria: 1. Age 18 years and above. 2. Ability to tolerate full course of pelvic radiotherapy+/- chemotherapy +/- brachytherapy. 3. Ability to understand and willingness to sign an informed consent document. 4. Should be willing to undergo extra biopsies and blood samples collection for translational research study. Cohort A: 1. Patients diagnosed with LACC Stage IB2 - IIIC1, as per FIGO 2018 Classification for Radical Cohort. 2. Stage IIIB-IVA where palliative RT is indicated for palliative cohort. 3. No previous irradiation to the pelvis or chemo therapy. Cohort B: 1. Patients diagnosed with LACC Stage IIIC2, as per FIGO 2018 Classification. 2. No previous irradiation to the pelvis or chemotherapy. Cohort C: 1. Patients diagnosed with gynecological cancer and presenting with need of infield radiation. 2. Planned for reirradiation. Exclusion Criteria: 1. Severe medical condition impairing complete treatment delivery. 2. Patients with immunocompromised states or active infection. 3. Patients on immunosuppressive drugs for other medical conditions. 4. Patients who will receive immune checkpoint inhibition (ICI) therapy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cervical carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cervical carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cervical carcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Tata Memorial Centre

    RECRUITING

    Mumbai, Maharashtra, 400012, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.